Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Dec 04, 2021 10:54pm
274 Views
Post# 34199394

RE:Partial response

RE:Partial response

A Partial Response means that upon a cystoscope exam, no visible cancer was detected in the bladder ( it appears cancer free visibly) but examination of Urine Cytology shows presence of cancer cells.  This means one of 2 things.  Either the bladder is actually cancer free and that the cancer cells appearing in the urine are from the ureter and not the bladder.  This would result in a CR as only the bladder is treated and the FDA does not expect the ureter to be Cancer free.  Or it could mean that there is cancer still present in the bladder, but which is too small or difficult to detect upon Cystoscope exam and hence why the Urine cytology appears positive.  Note that at trial entry, all of these patients were showing visible CIS and positive urine cytology.  That would lead to and NR.  About 21% of CIS patients also have cancer in the Ureter, so we could expect about 20% of CR patients to appear as PR initially until the cancer is proven to come from Ureter and so patient is reclassified as CR.  We see that about 20% of patients so far in Optimized treated group who are PR, so I'm hopeful that they end up reclassified as PR at end of trial, or a majority of them.  All IMO.

This bodes very well for us as there is a high chance that our PR patients will end up CR. IMHO 
"NMIBC patients with CIS were previously reported to have a higher incidence of UTUC recurrence than those without it (21.2% vs 2.3%, P < 0.001)24. Schwartz et al. showed that the UTUC recurrence rate was 13% in NMIBC patients with CIS, which was significantly higher than that in those without CIS (3.1%)25. A recent study demonstrated that the smoke load (over 20 pack-year) increased the risk of recurrence and progression (HR = 1.019 and 1.034, P = 0.00004 and 0.00002, respectively) in NMIBC patients treated with BCG, suggesting that the smoke load reduces the efficacy of BCG therapy26. These findings appear to support our results showing that concomitant CIS, but not a history of BCG, is an independent predictor of UTUC recurrence in NMIBC patients with a positive smoking history."
https://www.nature.com/articles/s41598-021-00184-y


Oilminerdeluxe wrote: Here's one. We all want as many CR patients as possible of course. However, me and my buddy wondered how to value a Partial Response? I mean, that must have some value too. If a tumor shrinks that must be a good thing. 

 

<< Previous
Bullboard Posts
Next >>